OSR Holdings, Inc.
OSRHW
$0.010.00%
At close · Oct 23, 2026
Mkt cap
—
EV/Sales
—
P/E ratio
—
FY2025 Revenue
$2.91M
EPS (TTM)
−$0.21
Gross Margin (FY2025)
20.40%
Profit Margin (FY2025)
−931.19%
Beta
—
Div yield
—
Sector
Healthcare
What matters now, from SEC filings and analyst ratings
Takeaway
A takeaway appears here once the latest filing has been analyzed.
Analysts
RatingsSector-relative grades for valuation, growth, profitability, momentum and revisions
Form 4 trades, last 90 days
Latest SEC filings
Source: SEC EDGAR · Latest filing Oct 28, 2026
Latest stored headlines
OSR Holdings, Inc. (OSRHW) is a biotechnology company listed on US.
Latest reported OSRHW revenue for 2025-12-31 was $2.9M. Net income was -$27.1M. Revenue was down 17.7% from 2024-12-31 to 2025-12-31.
Use this OSRHW research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full OSRHW income, balance, and cash tables.
† Total Debt: Derived from short-term debt only (no total or long-term debt stored).
OSR Holdings, Inc. (OSRHW) is a biotechnology company in the Healthcare sector.
Latest cached OSR Holdings, Inc. (OSRHW) revenue for Dec 31, 2025 was $2.9M. Net income was -$27.1M. Statements: https://lician.com/financials/osrhw
OSR Holdings, Inc. (OSRHW) cached previous close $0.01; day range $0.01 – $0.01. Session quote: https://lician.com/quote/osrhw
The latest cached OSRHW filing is 8-K · Oct 28, 2026. Filings: https://lician.com/sec/osrhw
Quant rating
MetricsHow it works—Not rated: no closing price in the last 7 days. Factor grades are still shown.
Lician Quant Grades · vs 548 Healthcare stocks · Nov 4, 2026
Next earnings
—
No upcoming report date on file.
Earnings
Short interest
900shares short
81.8 days to cover
−1.5% vs prior report
FINRA · settled Oct 15Short data
Range · 228 sessions
$0.01$0.07
Last close $0.01 · 85.0% below high
Low $0.01, high $0.07, last $0.01.Daily closesChart
SEC filings · latest fiscal year FY2025
Free shows the newest 2 years. FY2021–FY2023 on Pro
−17.7%
Revenue growth year over year
10-Q results and the earnings calendar
Revenue and EPS are GAAP diluted from the 10-Q. Beat or miss compares the calendar's actual with its estimate on the same basis (adj.), or revenue with the revenue estimate.
Institutional holders from SEC 13F filings